Inactive Instrument

ENTST BIO Stock Other OTC

Investment Holding Companies

End-of-day quote Other OTC Other stock markets
- ^USD	-

20-01-21	Entest Group, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2019	CI
19-12-20	Entest Group, Inc. Reports Earnings Results for the Full Year Ended August 31, 2019	CI

on all subscriptions*

Last hours

Enjoy this offer

* See conditions under "Our services"

Entest Group Inc is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. The Companyâ€™s current business plan is to seek new business opportunities or to engage in a business combination with an unidentified company. The Company has no operations and has not generated revenues.

Employees

Sector

Investment Holding Companies

More about the company

Market Cap	541K 467K 429K 404K 759K 51.05M 765K 5.08M 1.98M 25.05M 2.03M 1.99M 86.67M	P/E 2018	-0.92x	P/E 2019	12.6x
Enterprise Value	562K 485K 446K 420K 788K 53.05M 795K 5.28M 2.06M 26.03M 2.11M 2.06M 90.06M	EV / Sales 2018	-	EV / Sales 2019	-
Free-Float	98.54%	Yield 2018 *	-	Yield 2019	-

20-01-21	Entest Group, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2019	CI
19-12-20	Entest Group, Inc. Reports Earnings Results for the Full Year Ended August 31, 2019	CI
19-07-15	Entest Group, Inc. Reports Earnings Results for the Third Quarter Ended May 31, 2019	CI
19-01-22	Entest Group, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2018	CI
18-12-03	Entest Group, Inc. Announces Management Changes	CI
18-11-26	Peiwen Yu completed the acquisition of 48.3% stake in Entest Group, Inc. from Regen BioPharma, Inc., Bostonia Partners, Inc, Dunhill Ross Partners, Inc., Bio-Technology Partners Business Trust, David Koos and Sherman Family Trust.	CI
18-11-19	Peiwen Yu entered into an agreement to acquire 48.3% stake in Entest Group, Inc. from Regen BioPharma, Inc., Bostonia Partners, Inc, Dunhill Ross Partners, Inc., Bio-Technology Partners Business Trust, David Koos and Sherman Family Trust for $0.33 million.	CI
18-02-14	ENTB will Change its Name to ETNI	CI
15-11-26	Entest Group, Inc. Auditor Raises 'Going Concern' Doubt	CI
15-08-21	Entest Biomedical, Inc. will Change its Ticker to ENTB from ENTB.D	CI
15-07-27	Entest Biomedical, Inc. will Change its Ticker to ENTBD from ENTB	CI
14-07-16	Christine Ichim Joins Entest BioMedical Inc. as Director of Research	CI
13-03-06	Entest Biomedical Mulls Acquisitions	CI

20-01-21	ENTEST : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
20-01-07	ENTEST GROUP, INC. : Changes in Registrant's Certifying Accountant (form 8-K)	AQ
19-12-20	ENTEST : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
18-05-10	Entest Group, Inc. : Declares Property Dividend of 3,000,000 Common Shares of Zander Therapeutics Inc.	PR
17-09-13	Entest Biomedical : Zander Therapeutics, Inc. Announces Appointment of Dr. Robin Beat Gasser to Scientific Advisory Board	PR

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FACTORIAL ENERGY INC.	+1.44%	-29.12%	-	-	1.49B
EINRIDE AB	-7.08%	-36.96%	-	-	1.42B
AIR GLOBAL PLC	+1.88%	-2.97%	-	-	1.25B
CENTIEL AG	+2.31%	+22.84%	+388.34%	-60.20%	800M
ACC AVIATION HOLDINGS LTD.	+42.00%	+13.60%	+1,320.00%	+343.75%	709M
BAIN CAPITAL GSS INVESTMENT CORP.	-0.29%	-0.00%	-	-	598M
CANTOR EQUITY PARTNERS IV, INC.	+0.39%	+0.58%	-	-	591M
CHURCHILL CAPITAL CORP XI	+0.75%	+0.34%	-	-	571M
Average	+5.18%	+5.02%	+854.17%	+141.78%	928.51M
Weighted average by Cap.	+3.57%	+0.98%	+825.92%	+129.53%

	2018	2019
Net sales	-	-
Net income	-1.48M -1.27M -1.17M -1.1M -2.07M -139M -2.09M -13.89M -5.41M -68.43M -5.55M -5.43M -237M	192K 165K 152K 143K 269K 18.08M 271K 1.8M 701K 8.88M 719K 704K 30.7M
Net Debt	19.4K 16.74K 15.39K 14.48K 27.21K 1.83M 27.44K 182K 70.99K 899K 72.81K 71.26K 3.11M	21.2K 18.29K 16.81K 15.82K 29.74K 2M 29.99K 199K 77.57K 982K 79.56K 77.86K 3.4M

ENTST BIO Stock Other OTC

Stocks

Investment Holding Companies

Valuation: ENTST BIO

Latest news : ENTST BIO

Press Releases: ENTST BIO

Managers and Directors: ENTST BIO

Shell Companies

Financials

Company Profile